keyword
MENU ▼
Read by QxMD icon Read
search

Plerixafor

keyword
https://www.readbyqxmd.com/read/29742565/current-challenges-and-opportunities-in-the-management-of-antibody-mediated-rejection-in-lung-transplantation
#1
Amanda L Hulbert, Elizabeth N Pavlisko, Scott M Palmer
PURPOSE OF REVIEW: There is increasing recognition of the importance of antibody-mediated rejection (AMR) after lung transplantation. The development of donor-specific antibodies, a key feature of AMR, occurs in approximately 30% of lung transplant recipients and is associated with poor posttransplant outcomes. This review highlights recently developed AMR diagnostic criteria in lung transplantation, potential mechanisms that mediate the development of AMR, and discusses current and emerging treatment strategies for this significant, graft-limiting complication...
June 2018: Current Opinion in Organ Transplantation
https://www.readbyqxmd.com/read/29731423/evaluation-of-a-new-continuous-mononuclear-cell-collection-procedure-in-a-single-transplant-center-cohort-enriched-for-al-amyloidosis-patients
#2
Anita Pudusseri, India Smith, Diane Sarnacki, Dina Brauneis, Anthony Shelton, Vaishali Sanchorawala, J Mark Sloan, Shayna Sarosiek, Karen Quillen
BACKGROUND: The Spectra Optia continuous mononuclear cell (CMNC) program is newly available, and herein validated in a single-center cohort enriched with AL amyloidosis patients to collect a target CD34+ yield of 2.5 × 106 cells/kg within 2 days. METHODS: Consecutive autologous transplant patients in 2016 are included. Patients undergo leukapheresis with Optia CMNC and Spectra v4.7 over a 2-day cycle. Data collection includes collection efficiency, adverse events and engraftment kinetics...
April 26, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29728400/plerixafor-effectively-mobilizes-cd56-bright-nk-cells-in-blood-providing-an-allograft-predicted-to-protect-against-gvhd
#3
Peggy P C Wong, Amina Kariminia, David Jones, Connie J Eaves, Ronan Foley, Sabine Ivison, Stephen Couban, Kirk R Schultz
No abstract text is available yet for this article.
May 4, 2018: Blood
https://www.readbyqxmd.com/read/29724902/phase-i-trial-of-plerixafor-combined-with-decitabine-in-newly-diagnosed-older-patients-with-acute-myeloid-leukemia
#4
Gail J Roboz, Ellen K Ritchie, Yulia Dault, Linda Lam, Danielle C Marshall, Nicole M Cruz, Hsiao-Ting C Hsu, Duane C Hassane, Paul J Christos, Cindy Ippoliti, Joseph M Scandura, Monica L Guzman
Acute myeloid leukemia carries a dismal prognosis in older patients. The objective of this study was to investigate the safety and efficacy of decitabine combined with the CXCR4 antagonist plerixafor in newly diagnosed older patients with acute myeloid leukemia and to evaluate the effects of plerixafor on leukemia stem cells. Patients were treated with monthly cycles of decitabine 20 mg/m2 days 1-10 and escalating doses of plerixafor (320-810 mcg/kg) days 1-5. Sixty-nine patients were treated, with overall response rate 43%...
May 3, 2018: Haematologica
https://www.readbyqxmd.com/read/29712818/hematopoietic-stem-cell-mobilization-with-plerixafor-in-sickle-cell-disease
#5
EDITORIAL
Matthew M Hsieh, John F Tisdale
No abstract text is available yet for this article.
May 2018: Haematologica
https://www.readbyqxmd.com/read/29603795/optia%C3%A2-continuous-mononuclear-collection-cmnc-system-is-a-safe-and-efficient-system-for-hematopoietic-progenitor-cells-apheresis-hpc-a-collection-and-yields-a-lower-product-hematocrit-hct-than-the-cobe%C3%A2-spectra-system-a-retrospective-study
#6
Soumya Pandey, Michele Cottler-Fox
PURPOSE: We evaluated the Optia® continuous mononuclear collection (CMNC) system for hematopoietic progenitor cell-apheresis (HPC-A) collection (Terumo BCT, Lakewood, CO) compared to the COBE® Spectra (Terumo BCT, Lakewood, CO), including both large volume leukapheresis (LVL) and non-LVL collections. METHODS: We performed a retrospective data analysis of all autologous HPC-A collections with the Optia® CMNC system (n = 93; LVL = 59, non-LVL = 34) since implementation at our institution and compared it with a similar number of concurrent collections utilizing the COBE® Spectra (n = 96; LVL = 68, non-LVL = 28)...
March 30, 2018: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/29593457/platelet-count-before-peripheral-blood-stem-cell-mobilization-is-associated-with-the-need-for-plerixafor-but-not-with-the-collection-result
#7
Marc-Andrea Baertsch, Katharina Kriegsmann, Petra Pavel, Thomas Bruckner, Michael Hundemer, Mark Kriegsmann, Anthony D Ho, Hartmut Goldschmidt, Patrick Wuchter
Background: A low platelet count before mobilization has recurrently been identified as risk factor for poor mobilization. Methods: To determine the relevance of this finding for peripheral blood stem cell (PBSC) mobilization, including pre-emptive or rescue plerixafor in the case of poor mobilization, we retrospectively analyzed all patients undergoing PBSC collection at our institution between January 2014 and December 2015 (n = 380). Results: In total, 99% of the patients (377/380) successfully collected a minimum of 2 × 106 CD34+ cells/kg body weight sufficient for a single transplant...
January 2018: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/29550630/a-conditioning-regimen-with-plerixafor-is-safe-and-improves-the-outcome-of-tcr%C3%AE-%C3%AE-and-cd19-cell-depleted-stem-cell-transplantation-in-patients-with-wiskott-aldrich-syndrome
#8
Dmitry Balashov, Alexandra Laberko, Anna Shcherbina, Pavel Trakhtman, Dmitrii Abramov, Elena Gutovskaya, Svetlana Kozlovskaya, Larisa Shelikhova, Galina Novichkova, Michael Maschan, Alexander Rumiantsev, Alexei Maschan
Our initial experience with hematopoietic stem cell transplantation (HSCT) from a matched unrelated donor (MUD; n = 12) or a haploidentical related donor (n = 6) with T cell receptor (TCR)αβ+ /CD19+ graft depletion in patients with Wiskott-Aldrich syndrome (WAS) (n = 18) showed a dramatic decrease in the incidence of graft-versus-host disease (GVHD) and transplantation-related mortality, with an increased overall survival (OS) of 88.9%. Unfortunately, the treatment was associated with mixed myeloid donor chimerism and secondary graft dysfunction (severe thrombocytopenia, n = 2; graft rejection, n = 5)...
March 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29523889/peripheral-blood-stem-cell-mobilisation-with-g-csf-alone-versus-g-csf-and-cyclophosphamide-after-bortezomib-cyclophosphamide-and-dexamethasone-induction-in-multiple-myeloma
#9
Chong Chyn Chua, Hui Yin Lim, Khai Li Chai, Jeremy Ong, Shirlene Sim, Colin Wood, Michael Dickinson, Philip Campbell, Jennifer Hempton, Hayley King, Claire Dowsing, Krystal Bergin, Sharon Muir, Simon Gibbs, Andrew Grigg
Bortezomib-based induction is often used in transplant-eligible patients with myeloma. The optimal peripheral blood stem cell (PBSC) mobilisation strategy in this context is unclear. We reviewed the efficacy of G-CSF alone (G-alone) vs. G-CSF and cyclophosphamide (G-cyclo: standard dose: 1.5-2 g/m2 ; high dose: 3-4 g/m2 ) PBSC mobilisation strategies in 288 patients who only received bortezomib, cyclophosphamide and dexamethasone (VCD) induction prior to autograft across six apheresis centres from November 2012 to June 2017...
March 9, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29511032/amd3100-augments-the-efficacy-of-mesothelin-targeted-immune-activating-vic-008-in-mesothelioma-by-modulating-intratumoral-immunosuppression
#10
Binghao Li, Yang Zeng, Patrick M Reeves, Chongzhao Ran, Qiuyan Liu, Xiying Qu, Yingying Liang, Zhao Liu, Jianping Yuan, Pierre R Leblanc, Zhaoming Ye, Ann E Sluder, Jeffrey A Gelfand, Timothy A Brauns, Huabiao Chen, Mark C Poznansky
AMD3100 (plerixafor), a CXCR4 antagonist, has been demonstrated to suppress tumor growth and modulate intratumoral T-cell trafficking. However, the effect of AMD3100 on immunomodulation remains elusive. Here, we explored immunomodulation and antitumor efficacy of AMD3100 in combination with a previously developed mesothelin-targeted, immune-activating fusion protein, VIC-008, in two syngeneic, orthotopic models of malignant mesothelioma in immunocompetent mice. We showed that combination therapy significantly suppressed tumor growth and prolonged animal survival in two mouse models...
May 2018: Cancer Immunology Research
https://www.readbyqxmd.com/read/29473097/correction-to-a-phase-i-ii-study-of-plerixafor-in-combination-with-fludarabine-idarubicin-cytarabine-and-g-csf-pleriflag-regimen-for-the-treatment-of-patients-with-the-first-early-relapsed-or-refractory-acute-myeloid-leukemia
#11
David Martínez-Cuadrón, Blanca Boluda, Pilar Martínez, Juan Bergua, Rebeca Rodríguez-Veiga, Jordi Esteve, Susana Vives, Josefina Serrano, Belen Vidriales, Olga Salamero, Lourdes Cordón, Amparo Sempere, Ana Jiménez-Ubieto, Julio Prieto-Delgado, Marina Díaz-Beyá, Ana Garrido, Celina Benavente, José Antonio Pérez-Simón, Federico Moscardó, Miguel A Sanz, Pau Montesinos
The name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández in the original article.The original version of this article was revised: The name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández.
May 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29472357/plerixafor-enables-safe-rapid-efficient-mobilization-of-hematopoietic-stem-cells-in-sickle-cell-disease-patients-after-exchange-transfusion
#12
Chantal Lagresle-Peyrou, François Lefrère, Elisa Magrin, Jean-Antoine Ribeil, Oriana Romano, Leslie Weber, Alessandra Magnani, Hanem Sadek, Clémence Plantier, Aurélie Gabrion, Brigitte Ternaux, Tristan Félix, Chloé Couzin, Aurélie Stanislas, Jean-Marc Tréluyer, Lionel Lamhaut, Laure Joseph, Marianne Delville, Annarita Miccio, Isabelle André-Schmutz, Marina Cavazzana
Sickle cell disease is characterized by chronic anemia and vaso-occlusive crises, which eventually lead to multi-organ damage and premature death. Hematopoietic stem cell transplantation is the only curative treatment but it is limited by toxicity and poor availability of HLA-compatible donors. A gene therapy approach based on the autologous transplantation of lentiviral-corrected hematopoietic stem and progenitor cells was shown to be efficacious in one patient. However, alterations of the bone marrow environment and properties of the red blood cells hamper the harvesting and immunoselection of patients' stem cells from bone marrow...
May 2018: Haematologica
https://www.readbyqxmd.com/read/29461034/inhibition-of-hiv-fusion-by-small-molecule-agonists-through-efficacy-engineering-of-cxcr4
#13
Christian Berg, Viktorija Daugvilaite, Anne Steen, Astrid Sissel Jørgensen, Jon Våbenø, Mette Marie Rosenkilde
CXC chemokine receptor 4 (CXCR4) is involved in multiple physiological and pathological processes, notably as a coreceptor for human immunodeficiency virus (HIV) cell entry. Its broad expression pattern and vital biological importance make CXCR4 a troublesome drug target, as disruption of the interaction with its endogenous ligand, CXC chemokine ligand 12 (CXCL12), has severe consequences. In fact, only one CXCR4 drug, the bicyclam antagonist and HIV entry inhibitor AMD3100 (Plerixafor/Mozobil), has been approved for clinical use, however only for stem cell mobilization-a consequence of CXCR4 antagonism...
April 20, 2018: ACS Chemical Biology
https://www.readbyqxmd.com/read/29419425/safety-and-efficacy-of-plerixafor-dose-escalation-for-the-mobilization-of-cd34-hematopoietic-progenitor-cells-in-patients-with-sickle-cell-disease-interim-results
#14
Farid Boulad, Tsiporah Shore, Koen van Besien, Caterina Minniti, Mihaela Barbu-Stevanovic, Sylvie Wiener Fedus, Fabiana Perna, June Greenberg, Danielle Guarneri, Vijay Nandi, Audrey Mauguen, Karina Yazdanbakhsh, Michel Sadelain, Patricia A Shi
Gene therapy for sickle cell disease is limited by the yield of hematopoietic progenitor cells that can be harvested for transduction or gene editing. We therefore performed a phase I dose-escalation study of the hematopoietic progenitor cell mobilizing agent plerixafor to evaluate the efficacy and safety of standard dosing on peripheral blood CD34+ cell mobilization. Of 15 patients enrolled to date, only one was chronically transfused and ten were on hydroxyurea. Of eight patients who achieved a CD34+ cell concentration >30 cells/μL, six were on hydroxyurea...
May 2018: Haematologica
https://www.readbyqxmd.com/read/29417588/targeting-the-cxcl12-cxcr4-pathway-and-myeloid-cells-to-improve-radiation-treatment-of-locally-advanced-cervical-cancer
#15
REVIEW
Magali Lecavalier-Barsoum, Naz Chaudary, Kathy Han, Marianne Koritzinsky, Richard Hill, Michael Milosevic
Cervical cancer is the fourth most commonly diagnosed cancer and the fourth leading cause of cancer death in women worldwide. Approximately half of cervical cancer patients present with locally advanced disease, for which surgery is not an option. These cases are nonetheless potentially curable with radiotherapy and cisplatin chemotherapy. Unfortunately, some tumours are resistant to treatment, and lymph node and distant recurrences are major problems in patients with advanced disease at diagnosis. New targeted treatments that can overcome treatment resistance and reduce metastases are urgently needed...
February 8, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29410180/plerixafor-plus-granulocyte-colony-stimulating-factor-for-patients-with-non-hodgkin-lymphoma-and-multiple-myeloma-long-term-follow-up-report
#16
Ivana N Micallef, Patrick J Stiff, Auayporn P Nademanee, Richard T Maziarz, Mitchell E Horwitz, Edward A Stadtmauer, Jonathan L Kaufman, John M McCarty, Rita Vargo, Peter D Cheverton, Martin Struijs, Brian Bolwell, John F DiPersio
The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with non-Hodgkin lymphoma (NHL; n = 167) and multiple myeloma (MM; n = 163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240 µg/kg plerixafor plus 10 µg/kg G-CSF, or placebo plus 10 µg/kg G-CSF to mobilize and collect CD34+ cells for autologous hematopoietic stem cell transplantation...
February 2, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29392425/a-phase-i-ii-study-of-plerixafor-in-combination-with-fludarabine-idarubicin-cytarabine-and-g-csf-pleriflag-regimen-for-the-treatment-of-patients-with-the-first-early-relapsed-or-refractory-acute-myeloid-leukemia
#17
MULTICENTER STUDY
David Martínez-Cuadrón, Blanca Boluda, Pilar Martínez, Juan Bergua, Rebeca Rodríguez-Veiga, Jordi Esteve, Susana Vives, Josefina Serrano, Belen Vidriales, Olga Salamero, Lourdes Cordón, Amparo Sempere, Ana Jiménez-Ubieto, Julio Prieto-Delgado, Marina Díaz-Beyá, Ana Garrido, Celina Benavente, José Antonio Pérez-Simón, Federico Moscardó, Miguel A Sanz, Pau Montesinos
Clinical outcomes of patients with acute myeloid leukemia (AML) showing the first primary refractory or early-relapsed disease remain very poor. The Programa Español de Tratamientos en Hematología (PETHEMA) group designed a phase I-II trial using FLAG-Ida (fludarabine, idarubicin, cytarabine, and G-CSF) plus high-dose intravenous plerixafor, a molecule inducing mobilization of blasts through the SDF-1α-CXCR4 axis blockade and potentially leading to chemosensitization of the leukemic cells. We aimed to establish a recommended phase 2 dose (RP2D) of plerixafor plus FLAG-Ida, as well as the efficacy and safety of this combination for early-relapsed (first complete remission (CR/CRi) < 12 months) or primary refractory AML...
May 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29391335/use-of-plerixafor-to-mobilize-a-healthy-donor-infected-with-influenza-a
#18
Mahmut Yeral, Pelin Aytan, Can Boğa
No abstract text is available yet for this article.
February 2, 2018: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
https://www.readbyqxmd.com/read/29382856/dynamic-cellular-phynotyping-defines-specific-mobilization-mechanisms-of-human-hematopoietic-stem-and-progenitor-cells-induced-by-sdf1%C3%AE-versus-synthetic-agents
#19
Cornelia Monzel, Alexandra S Becker, Rainer Saffrich, Patrick Wuchter, Volker Eckstein, Anthony D Ho, Motomu Tanaka
Efficient mobilization of hematopoietic stem and progenitor cells (HSPC) is one of the most crucial issues for harvesting an adequate amount of peripheral HSPC for successful clinical transplantation. Applying well-defined surrogate models for the bone marrow niche, live cell imaging techniques, and novel tools in statistical physics, we have quantified the functionality of two mobilization agents that have been applied in the clinic, NOX-A12 and AMD3100 (plerixafor), as compared to a naturally occurring chemokine in the bone marrow, SDF1α...
January 30, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29339268/incidence-of-second-primary-malignancies-after-autologous-transplantation-for-multiple-myeloma-in-the-era-of-novel-agents
#20
Firoozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, Linda Koster, Didier Blaise, Péter Reményi, Nigel H Russell, Per Ljungman, Guido Kobbe, Jane Apperley, Marek Trneny, Marta Krejci, Wieslaw Wiktor-Jedrzejczak, James F Sanchez, Nicolaas Schaap, Cecilia Isaksson, Stig Lenhoff, Paul Browne, Christof Scheid, Keith M O Wilson, Ibrahim Yakoub-Agha, Soledad González Muñiz, Stefan Schönland, Curly Morris, Laurent Garderet, Nicolaus Kröger
The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers...
January 12, 2018: Biology of Blood and Marrow Transplantation
keyword
keyword
44247
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"